| 1 |
32352244 | Buparlisib in combination with tamoxifen in pretreated patients with hormone receptor-positive, HER2-negative advanced breast cancer molecularly stratified for PIK3CA mutations and loss of PTEN expression. | 2020 Jul |
1 |
| 2 |
30651399 | Exploring Biomarkers of Phosphoinositide 3-Kinase Pathway Activation in the Treatment of Hormone Receptor Positive, Human Epidermal Growth Receptor 2 Negative Advanced Breast Cancer. | 2019 Mar |
1 |
| 3 |
31159599 | Benefits versus risk profile of buparlisib for the treatment of breast cancer. | 2019 Jul |
1 |
| 4 |
29198055 | Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy. | 2018 Apr |
6 |
| 5 |
29223745 | Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial. | 2018 Jan |
1 |
| 6 |
29430197 | Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date. | 2018 |
1 |
| 7 |
30241001 | Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2. | 2018 Nov |
2 |
| 8 |
27803006 | A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4). | 2017 Feb 1 |
2 |
| 9 |
28576675 | Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. | 2017 Jul |
1 |
| 10 |
28923573 | Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE). | 2017 Nov |
1 |
| 11 |
28950146 | PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer. | 2017 Nov |
3 |
| 12 |
27175939 | The combination of NVP-BKM120 with trastuzumab or RAD001 synergistically inhibits the growth of breast cancer stem cells in vivo. | 2016 Jul |
1 |
| 13 |
24470511 | Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapy. | 2014 Apr 1 |
3 |
| 14 |
22188813 | Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. | 2012 Feb |
1 |